Skip to content

Dr. Raphael Hofstein’s guest column posted on Biotechnology Focus

Raphael Hofstein
Raphael Hofstein, president and CEO of MaRS Innovation.

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Raphael Hofstein.

The article examines how to build a strong biotechnology cluster from an academic base in the midst of a global recession.

Here’s an excerpt:

Gone are the days of large-scale, well-funded, in-house departments with resources to liberally support academic and start-up collaborations. Financial pressures and the economic downturn have made it clear that the go-it-alone model is no longer sustainable, and industry players are recognizing that they don’t have a monopoly on research acumen and disruptive ideas. Simultaneously, industry has expressed less interest in investing in early-stage technologies that carry significant risk. They remain receptive to the research emerging from academic enterprise, but need a means of bridging the gap that technologies face as they move from the bench to the market.

Continue Reading

VP Joel Liederman’s Financial Post article on mitigating innovation risk

Joel Liederman, vice-president (physical sciences)
Joel Liederman, MI’s vice-president of business development and physical sciences

MaRS Innovation’s Vice-President of Business Development and Physical Sciences Joel Liederman, has published an article in the Financial Post about strategies to mitigate risk within the innovation space.

The article, titled “Innovation Success Means Mitigating Risk,” is featured in the newspaper’s Productive Conversations section.

Continue Reading
Back To Top